Peptide Initiative
Back to Exenatide

Clinical trials

Every registered trial of Exenatide

353 studies, 9 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Exenatide has been studied in people a great deal.
  • 353 registered studies in total.
  • 9 are still enrolling people, so this is active research, not just history.

What kind of research

  • 328 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 65,835 people took part in those.
  • A further 25 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 353 of 353 trials for Exenatide.

  • NCT07497399 Phase 2Recruiting120 enrolled2026

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Johns Hopkins University

    Multiple Sclerosis

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07347080 Early Phase 1Recruiting9 enrolled2026

    A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

    The First Affiliated Hospital of Henan University of Science and Technology

    T2DM

  • 2024-519014-31-00 Revoked30 enrolled2025

    CHDR2418

    Centre for Human Drug Research

    Cardiovascular and metabolic diseases

  • NCT05670379 Phase 1Completed24 enrolled2024

    Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

    Vivani Medical, Inc

    Overweight and Obesity · Type2diabetes

  • NCT06888167 Recruiting40 enrolled2024

    Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.

    Azienda Ospedaliero-Universitaria di Parma

    Healthy Volunteer

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05663515 Recruiting24,000 enrolled2024

    A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

    AstraZeneca

    Pancreatic Cancer

  • 2024-516755-40-00 Ongoing10 enrolled2024

    Exendin PET/CT for imaging of paragangliomas

    Stichting Radboud universitair medisch centrum

    paragangliomas

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06252623 Phase 1Withdrawn2024

    Exenatide For Reducing the Reinforcing Effects of Cocaine

    Christopher D. Verrico

    Cocaine Use Disorder

  • NCT06257966 Phase 3Active Not Recruiting600 enrolled2024

    A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

    Beijing Dongfang Biotech Co., Ltd.

    Type2 Diabetes Mellitus

  • NCT06254014 Phase 3Active Not Recruiting270 enrolled2024

    A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

    Beijing Dongfang Biotech Co., Ltd.

    Type 2 Diabetes Mellitus

  • NCT02586831 Phase 1/2Withdrawn2024

    Diabetes Islet Preservation Immune Treatment

    Camillo Ricordi and Jay Skyler

    Diabetes Mellitus, Type 1 · Hypoglycemia · Autoimmune Diseases · Diabetes Mellitus

  • NCT06247748 Phase 1Completed28 enrolled2023

    Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

    Beijing Dongfang Biotech Co., Ltd.

    Diabetes Mellitus, Type 2 · Overweight

  • NCT07309094 Recruiting250 enrolled2023

    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    Cardenal Herrera University

    Chronic Kidney Disease stage3 · Chronic Kidney Disease stage4 · Chronic Kidney Disease Stage 1 · Chronic Kidney Disease Stage 2

  • NCT05482789 Phase 4Recruiting13 enrolled2023

    Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

    Maisa N. Feghali, MD

    Gestational Diabetes

  • NCT05622123 Phase 2Unknown20 enrolled2023

    BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

    Radboud University Medical Center

    Type 1 Diabetes

  • NCT05610800 Phase 2Completed140 enrolled2022

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    The University of Texas Health Science Center, Houston

    Smoking Cessation · Weight Gain

  • NCT05347147 Phase 3Terminated14 enrolled2022

    A Trial to Determine the Efficacy and Safety of Presendin in IIH

    Invex Therapeutics Ltd.

    Idiopathic Intracranial Hypertension

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05418907 Unknown10 enrolled2022

    Exendin PET/CT for Imaging of Paragangliomas

    Radboud University Medical Center

    Paraganglioma

  • NCT05356104 Phase 2Recruiting110 enrolled2022

    GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

    Chinese University of Hong Kong

    Cerebral Small Vessel Disease

  • NCT05662189 Recruiting70 enrolled2022

    Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

    Azienda Ospedaliero-Universitaria di Parma

    Type1diabetes · Type2diabetes · Pre Diabetes · Hyperinsulinism

  • NCT04307797 Phase 4Completed10 enrolled2022

    Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

    Cambridge University Hospitals NHS Foundation Trust

    Type 2 Diabetes · Obesity

  • NCT05034783 Early Phase 1Unknown20 enrolled2021

    [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

    Peking Union Medical College Hospital

    Insulinoma

  • NCT04897802 Phase 4Completed42 enrolled2021

    Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

    Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    Hypopituitarism · Central Diabetes Insipidus · Panhypopituitarism · Psychological Disorder

  • NCT05220917 Active Not Recruiting781,430 enrolled2021

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital

    Cardiovascular Events · Type2 Diabetes · Renal Disease

  • NCT05073692 Completed241,981 enrolled2021

    Comparison of Type 2 Diabetes Pharmacotherapy Regimens

    Kaiser Permanente

    Type 2 Diabetes Mellitus · Cardiovascular Diseases

  • NCT04615910 Phase 2Unknown30 enrolled2021

    A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass

    Radboud University Medical Center

    Diabetes Mellitus

  • NCT04941521 Phase 1/2Completed3 enrolled2021

    Exenatide for Treating Cocaine Use Disorder

    The University of Texas Health Science Center, Houston

    Cocaine Use Disorder

  • 2024-515588-67-00 Revoked52 enrolled2021

    Identification and clinical relevance of an oxytocin-deficient state: randomized, crossover, placebo-controlled pilot physiopathological study: GLP1 Study.

    Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

    Hypopituarism

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04909333 Completed29 enrolled2021

    Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

    University Hospital, Basel, Switzerland

    Endogenous Hyperinsulinism

  • NCT04520490 Phase 3Active Not Recruiting63 enrolled2021

    Brain Activation and Satiety in Children 2

    Seattle Children's Hospital

    Childhood Obesity

  • NCT04969627 Phase 4Completed60 enrolled2021

    Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

    Bing He

    Polycystic Ovary Syndrome

  • NCT04431713 Phase 2Completed50 enrolled2020

    Exenatide Once-weekly as a Treatment for Multiple System Atrophy

    University College, London

    Multiple System Atrophy

  • NCT04979611 Phase 1Unknown60 enrolled2020

    The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

    First Affiliated Hospital of Fujian Medical University

    Insulinoma

  • NCT04001231 Phase 1Withdrawn2020

    Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes

  • NCT04379856 Phase 1/2Unknown12 enrolled2020

    Proof of Concept Study in Patients With Short Bowel Syndrome

    9 Meters Biopharma, Inc.

    Short Bowel Syndrome

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04504396 Phase 3Completed620 enrolled2020

    Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

    PegBio Co., Ltd.

    Type 2 Diabetes Mellitus (T2DM)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04504370 Phase 3Completed273 enrolled2020

    Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

    PegBio Co., Ltd.

    Type 2 Diabetes Mellitus (T2DM)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04269642 Phase 2Unknown99 enrolled2020

    SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

    Peptron, Inc.

    Early Parkinson's Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04154072 Phase 2Completed255 enrolled2020

    A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    Neuraly, Inc.

    Parkinson Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04305002 Phase 2Unknown60 enrolled2020

    Exenatide Treatment in Parkinson's Disease

    Center for Neurology, Stockholm

    Parkinson Disease

  • 2024-520069-30-00 Revoked60 enrolled2020

    Exenatide

    Region Stockholm – SLSO

    Parkinson's disease

  • NCT04232969 Phase 3Completed194 enrolled2020

    Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

    University College, London

    Parkinson's Disease

  • NCT04303819 Completed38 enrolled2020

    The Effect of Exenatide on Fasting Bile Acids

    Beijing Chao Yang Hospital

    Type 2 Diabetes Mellitus in Obese

  • NCT04733508 Unknown28 enrolled2019

    Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

    Radboud University Medical Center

    Diabetes Mellitus · Diabetes Mellitus, Type 2

  • NCT04159766 Phase 2Completed20 enrolled2019

    A Study With NLY01 in Subjects With Type 2 Diabetes

    Neuraly, Inc.

    Type2 Diabetes · Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04029272 Phase 4Unknown80 enrolled2019

    Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

    Peking Union Medical College Hospital

    Polycystic Ovary Syndrome

  • NCT03970044 Phase 4Completed67 enrolled2019

    Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

    Consano Clinical Research, LLC

    Diabetes Mellitus, Type 2

  • NCT03923114 Completed20 enrolled2019

    Imaging Pituitary ActiVation by Exendin

    Radboud University Medical Center

    Diabetes Mellitus, Type 2

  • NCT03961256 Phase 2Completed9 enrolled2019

    Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

    Mayo Clinic

    Pre Diabetes

  • NCT04185350 Early Phase 1Unknown60 enrolled2019

    Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma

    Nanjing First Hospital, Nanjing Medical University

    Insulinoma

  • NCT03645408 Phase 1Terminated8 enrolled2019

    The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

    Boston Medical Center

    Alcohol Use Disorder

  • NCT03835013 Completed26 enrolled2019

    Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

    Cambridge University Hospitals NHS Foundation Trust

    Cardiovascular Diseases

  • NCT06725693 Recruiting500 enrolled2019

    Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

    Tianjin Medical University

    GLP1-R-related Disease · Tumor · Insulinoma · Positron Emission Tomography

  • NCT03672604 Phase 1Completed96 enrolled2018

    A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

    Neuraly, Inc.

    Safety and Tolerability in Healthy Volunteers

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03671733 Phase 3Unknown150 enrolled2018

    Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

    Xiangya Hospital of Central South University

    Obesity

  • NCT03456687 Phase 1Completed5 enrolled2018

    Effects of Exenatide on Motor Function and the Brain

    University of Florida

    Parkinson's Disease

  • NCT03331289 Phase 4Completed107 enrolled2018

    Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

    The University of Texas Health Science Center at San Antonio

    Diabetes Mellitus, Type 2

  • NCT03419624 Phase 3Terminated13 enrolled2018

    The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

    Universitätsklinikum Hamburg-Eppendorf

    Obesity · Diabetes Mellitus, Type 2

  • NCT03768518 Unknown40 enrolled2018

    GLP-1 Receptor Expression in CHI

    Radboud University Medical Center

    Congenital Hyperinsulinism

  • NCT03383068 Phase 4Unknown160 enrolled2018

    Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

    RenJi Hospital

    PCOS · Impaired Glucose Tolerance

  • NCT03350191 Phase 1Completed13 enrolled2017

    A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02981069 Phase 4Completed90 enrolled2017

    Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

    The University of Texas Health Science Center at San Antonio

    Diabetes Mellitus, Type 2

  • NCT03352869 Phase 4Completed183 enrolled2017

    Research of Exenatide for Overweight/Obese PCOS Patients With IGR

    RenJi Hospital

    Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

  • NCT03287076 Phase 2Unknown350 enrolled2017

    Trial of EXenatide in Acute Ischaemic Stroke

    Neuroscience Trials Australia

    Acute Ischemic Stroke

  • NCT03444142 Phase 4Unknown30 enrolled2017

    Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

    University of Guadalajara

    Diabetes Mellitus, Type 2

  • RESILIENT

    University of Liverpool

    Specialty: Diabetes, Primary sub-specialty: Type 2; UKCRC code/ Disease: Metabolic and Endocrine/ Diabetes mellitus

  • NCT03361098 Phase 4Completed65 enrolled2017

    DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

    Amsterdam UMC, location VUmc

    Type 2 Diabetes Mellitus · Obesity

  • NCT03160261 Phase 4Completed10 enrolled2017

    Effect of Exenatide on Cortisol Secretion

    University of Tartu

    Healthy

  • NCT03232112 Phase 2Completed152 enrolled2017

    Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

    Anders Fink-Jensen, MD, DMSci

    Alcohol Dependence, in Remission · Addiction, Alcohol

  • IIH Pressure - a new treatment for raised brain pressure in Idiopathic Intracranial Hypertension

    University of Birmingham

    Idiopathic intracranial hypertension

  • NCT03167411 Phase 1Completed20 enrolled2017

    Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

    Theracos

    Type2 Diabetes Mellitus

  • NCT03007329 Phase 4Completed34 enrolled2017

    Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

    Medical University of Vienna

    Steatosis, Liver · Type2 Diabetes

  • NCT03060980 Phase 3Terminated245 enrolled2017

    Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

    Intarcia Therapeutics

    Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02735031 Phase 2/3Completed10 enrolled2017

    Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

    Radboud University Medical Center

    Diabetes Mellitus, Type 1 · Hypoglycemia

  • NCT03018665 Phase 4Unknown200 enrolled2017

    A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

    The First Hospital of Jilin University

    Diabetes Mellitus, Type 2

  • NCT02860923 Phase 3Completed42 enrolled2017

    Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

    University Hospital, Bordeaux

    Craniopharyngiomas · Hypothalamic Obesity

  • NCT03029351 Phase 4Terminated15 enrolled2017

    GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

    University at Buffalo

    Type2 Diabetes · Kidney Diseases

  • NCT03199261 Phase 1Completed24 enrolled2016

    A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects

    CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    Type 2 Diabetes

  • NCT03017352 Phase 2Completed108 enrolled2016

    Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

    Filip Krag Knop

    Diabetes Mellitus, Type 1

  • NCT03182296 Unknown24 enrolled2016

    Visualizing Beta Cells in Patients With a History of Gestational Diabetes

    Radboud University Medical Center

    Gestational Diabetes

  • NCT02962492 Completed70 enrolled2016

    An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

    University at Buffalo

    Evaluate Ketogenic Stress

  • NCT03182231 Phase 1/2Unknown12 enrolled2016

    GLP1-imaging Before and After Bariatric Surgery

    Radboud University Medical Center

    Diabetes Mellitus, Type 2 · Bariatric Surgery Candidate

  • NCT02793154 Phase 4Terminated4 enrolled2016

    An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

  • NCT02802514 Phase 4Terminated5 enrolled2016

    A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

    GlaxoSmithKline

    Diabetes Mellitus

  • NCT02838589 Phase 2Completed30 enrolled2016

    The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

    Christina Kruuse

    Stroke

  • NCT03002675 Phase 4Unknown24 enrolled2016

    Exenatide and Brown Adipose Tissue

    Ingrid Jazet

    Obesity

  • NCT02895672 Completed150 enrolled2016

    GLP-1/Basal Insulin Combination Therapy

    Albany College of Pharmacy and Health Sciences

    Type 2 Diabetes Mellitus

  • NCT02829502 Phase 2Unknown30 enrolled2016

    The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

    Christina Kruuse

    Ischemic Stroke

  • NCT02787551 Phase 3Completed514 enrolled2016

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02975297 Phase 1/2Completed84 enrolled2016

    Exenatide Once Weekly for Smoking Cessation

    The University of Texas Health Science Center, Houston

    Smoking Cessation

  • NCT02811484 Phase 4Withdrawn2016

    Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

    Weill Medical College of Cornell University

    Diabetes Mellitus, Type 2

  • NCT05762744 Phase 1Terminated63 enrolled2016

    Pharmacogenomics of GLP1 Receptor Agonists

    University of Maryland, Baltimore

    Type 2 Diabetes

  • NCT02690883 Phase 4Completed92 enrolled2016

    Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

    Nanfang Hospital, Southern Medical University

    Diabetic Nephropathies

  • NCT03182192 Phase 1Unknown12 enrolled2016

    GLP1R-imaging in Hypoglycemia

    Radboud University Medical Center

    Hypoglycemia

  • NCT02635386 Phase 3Completed119 enrolled2016

    EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

    Woman's

    Polycystic Ovary Syndrome · Obesity

  • NCT02664441 Phase 3Completed42 enrolled2016

    Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

    Seattle Children's Hospital

    Hypothalamic Obesity

  • NCT02404376 Phase 3Completed378 enrolled2016

    COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

    Hospital Universitari Vall d'Hebron Research Institute

    ST Elevation Acute Myocardial Infarction

  • NCT02673931 Active Not Recruiting1,400 enrolled2016

    GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

    Rigshospitalet, Denmark

    Coronary Disease · Shock, Cardiogenic · Renal Failure · Stroke

  • NCT02847403 Phase 3Unknown40 enrolled2016

    Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

    Azienda Ospedaliero-Universitaria di Parma

    Dysglycemia · Cognitive Deficit

  • NCT02685852 Phase 1Completed11 enrolled2016

    Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

    University of Minnesota

    Hyperinsulinemic Hypoglycemia

  • NCT02533453 Phase 4Completed110 enrolled2016

    A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT02650479 Phase 1Completed82 enrolled2016

    Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

    Intarcia Therapeutics

    Healthy Adult Male and Female Volunteers

  • NCT02496611 Phase 2Completed100 enrolled2015

    Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

    University of Minnesota

    Severe Obesity

  • NCT02621489 Phase 4Completed38 enrolled2015

    Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

    Karolinska Institutet

    Atherosclerosis · Diabetes · Restenosis

  • NCT02638805 Phase 3Completed136 enrolled2015

    Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

    Intarcia Therapeutics

    Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02641899 Phase 1Completed33 enrolled2015

    Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

    Intarcia Therapeutics

    Healthy

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02641990 Phase 1Completed28 enrolled2015

    Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

    Intarcia Therapeutics

    Healthy Adult Premenopausal Female Volunteers

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03889496 Terminated12 enrolled2015

    Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

    Radboud University Medical Center

    Diabetes Mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02449603 Phase 4Completed150 enrolled2015

    Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

    Xijing Hospital

    Type 2 Diabetes Mellitus

  • NCT02251431 Phase 3Completed57 enrolled2015

    Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

    Baylor Research Institute

    Type 2 Diabetes Mellitus · Chronic Kidney Disease · Left Ventricular Diastolic Dysfunction

  • NCT02584075 Phase 4Unknown100 enrolled2015

    Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

    Beijing Chao Yang Hospital

    Coronary Endothelial Function

  • NCT02455076 Phase 4Completed150 enrolled2015

    Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

    Emory University

    Type 2 Diabetes

  • NCT02794402 Phase 2Completed44 enrolled2015

    Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI

    Uppsala University

    Obesity

  • NCT02467920 Phase 4Completed349 enrolled2015

    Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

    Huazhong University of Science and Technology

    Type 2 Diabetes Mellitus

  • NCT02917057 Completed6,024 enrolled2015

    Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

    AstraZeneca

    Type 2 Diabetes

  • NCT02690987 Early Phase 1Unknown95 enrolled2015

    Gut Hormones in Obesity, Nicotine and Alcohol Dependence

    Imperial College London

    Obesity · Smoking Cessation · Alcoholism

  • NCT02058940 Phase 4Completed8 enrolled2015

    Intravenous Exenatide in Patients With Acute Brain Injury

    University of North Carolina, Chapel Hill

    Brain Injuries

  • NCT02541734 Phase 1/2Completed12 enrolled2015

    Effect of Gelofusine on GLP1-receptor Imaging

    Radboud University Medical Center

    Diabetes Mellitus, Non-Insulin-Dependent · Diabetes Mellitus

  • NCT02584582 Phase 2/3Unknown10 enrolled2015

    The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

    Hvidovre University Hospital

    Type 1 Diabetes

  • NCT02987348 Completed18,000 enrolled2015

    Clinical Outcomes of Exenatide Versus Basal Insulin

    AstraZeneca

    Type 2 Diabetes

  • NCT02432976 Phase 2/3Completed64 enrolled2015

    Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients

    Centre Hospitalier Universitaire de Besancon

    Quality of Life

  • NCT03059719 Phase 1Completed36 enrolled2015

    Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

    PegBio Co., Ltd.

    Type II Diabetes Mellitus

  • NCT03189953 Phase 1/2Completed56 enrolled2015

    68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH

    Radboud University Medical Center

    Insulinoma

  • NCT02303730 Phase 4Completed76 enrolled2015

    Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

    Fudan University

    Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

  • NCT02887625 Unknown410 enrolled2015

    Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

    Dr. Muhammad Abdulghani

    Type 2 Diabetes

  • NCT02344641 Unknown234 enrolled2015

    Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

    Chinese Academy of Medical Sciences, Fuwai Hospital

    Type 2 Diabetes Mellitus · Heart Failure

  • NCT02325960 Phase 4Completed44 enrolled2015

    A Comparison of Exenatide and Insulin Glargine

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Type 2 Diabetes

  • NCT01969149 Phase 2/3Completed110 enrolled2015

    Exenatide for Stress Hyperglycemia

    Centre Hospitalier Universitaire de Besancon

    Stress Hyperglycemia

  • NCT02380521 Phase 4Completed60 enrolled2015

    Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

    University of Palermo

    Type 2 Diabetes Mellitus

  • NCT02313220 Phase 2Completed50 enrolled2014

    Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

    Uppsala University

    Obesity

  • NCT02288273 Phase 4Completed239 enrolled2014

    Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

    AstraZeneca

    Type 2 Diabetes

  • NCT02320045 Phase 1Completed38 enrolled2014

    Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

    Intarcia Therapeutics

    Renal Insufficiency

  • NCT02302976 Phase 1Completed13 enrolled2014

    GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

    Yale University

    Cocaine Dependence

  • NCT02974244 Completed7,000 enrolled2014

    Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

    AstraZeneca

    Type 2 Diabetes

  • NCT02244164 Terminated5 enrolled2014

    Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

    Erasme University Hospital

    Type 2 Diabetes · Incretinomimetics · Pancreas

  • NCT02501850 Phase 4Unknown40 enrolled2014

    The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

    Hospital Universitari Vall d'Hebron Research Institute

    Diabetes Mellitus Type 2

  • NCT02229383 Phase 3Completed464 enrolled2014

    Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus

  • NCT02229396 Phase 3Completed695 enrolled2014

    Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

    AstraZeneca

    Diabetes Mellitus

  • NCT02417142 Phase 4Completed70 enrolled2014

    Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

    University of Massachusetts, Worcester

    Schizophrenia · Schizoaffective Disorder

  • NCT02194595 Phase 3Completed105 enrolled2014

    Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

    Mount Sinai Hospital, Canada

    Type 2 Diabetes

  • NCT02118376 Unknown20 enrolled2014

    Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

    Shanghai 10th People's Hospital

    Obesity

  • NCT02157974 Phase 2/3Completed92 enrolled2014

    Liver and Fat Regulation in Overweight Adolescent Girls

    University of Colorado, Denver

    Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity

  • NCT02170324 Phase 4Completed20 enrolled2014

    GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

    Xiang Guang-da

    Obesity

  • NCT01971242 Phase 2Completed60 enrolled2014

    Trial of Exenatide for Parkinson's Disease

    University College, London

    Parkinson's Disease

  • NCT02162550 Phase 4Unknown148 enrolled2014

    Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

    Phoenix VA Health Care System

    Type 2 Diabetes

  • NCT02160990 Phase 4Completed20 enrolled2014

    Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

    Mayo Clinic

    Obesity

  • NCT02442791 Completed120 enrolled2014

    GLP-1 Analogs for Neuroprotection After Cardiac Arrest

    Jesper Kjaergaard

    Cardiac Arrest · Coma

  • NCT02150707 Completed17 enrolled2014

    The Differential Effects of Diabetes Therapy on Inflammation

    University College Dublin

    Diabetic Nephropathy · Type 2 Diabetes

  • NCT02119819 Phase 2Completed420 enrolled2014

    A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

    OPKO Health, Inc.

    Diabetes Mellitus, Type 2

  • NCT02104739 Phase 4Completed21 enrolled2014

    Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

    The University of Texas Health Science Center, Houston

    Prediabetes · Obesity

  • NCT02456428 Completed1,499,650 enrolled2014

    Incretin-based Drugs and the Risk of Heart Failure

    Canadian Network for Observational Drug Effect Studies, CNODES

    Type 2 Diabetes Mellitus

  • NCT02475499 Completed886,172 enrolled2014

    Incretin-based Drugs and Pancreatic Cancer

    Canadian Network for Observational Drug Effect Studies, CNODES

    Diabetes Mellitus, Type 2

  • NCT02476760 Completed1,417,914 enrolled2014

    Incretin-based Drugs and Acute Pancreatitis

    Canadian Network for Observational Drug Effect Studies, CNODES

    Diabetes Mellitus, Type 2

  • NCT02129985 Phase 4Unknown100 enrolled2014

    Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

    xiaolong zhao

    Type 2 Diabetes

  • NCT02560376 Early Phase 1Unknown100 enrolled2014

    68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

    Peking Union Medical College Hospital

    Insulinoma · Nesidioblastosis

  • NCT02081118 Phase 2Completed209 enrolled2014

    Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Hanmi Pharmaceutical Company Limited

    Type 2 Diabetes

  • NCT01938235 Phase 2Unknown198 enrolled2014

    Exenatide for Myocardial Protection During Reperfusion Study

    University Health Network, Toronto

    Myocardial Infarction

  • NCT02072096 Phase 4Terminated192 enrolled2014

    A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

  • NCT02127541 Completed52 enrolled2014

    New Imaging Procedure for the Localisation of Insulinoma

    University Hospital, Basel, Switzerland

    Endogenous Hyperinsulinaemic Hypoglycaemia

  • NCT02057172 Phase 2Completed254 enrolled2014

    Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Hanmi Pharmaceutical Company Limited

    Type 2 Diabetes

  • NCT01885208 Phase 3Completed813 enrolled2013

    Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02020616 Phase 1/2Terminated60 enrolled2013

    A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

    Eli Lilly and Company

    Type 2 Diabetes Mellitus

  • NCT02059564 Phase 1Unknown44 enrolled2013

    A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

    Hanmi Pharmaceutical Company Limited

    Diabetes Mellitus

  • NCT01988545 Unknown8 enrolled2013

    GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

    Zealand University Hospital

    Healthy

  • NCT02092597 Phase 4Completed42 enrolled2013

    Safety Evaluation of Adverse Reactions in Diabetes

    Charles University, Czech Republic

    Type 2 Diabetes Mellitus

  • NCT01928329 Phase 2Completed79 enrolled2013

    A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

    Yale University

    Type I Diabetes

  • NCT00572689 Phase 4Withdrawn2013

    Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

    Georgetown University

    Gestational Diabetes

  • NCT01934816 Terminated2 enrolled2013

    Incretin and KATP Channels

    Katarina Kos

    Healthy Subjects

  • NCT01857895 Phase 1Completed10 enrolled2013

    Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

    GlaxoSmithKline

    Obesity

  • NCT01785771 Phase 3Terminated100 enrolled2013

    A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

    Intarcia Therapeutics

    Type 2 Diabetes

  • NCT01455870 Phase 3Completed535 enrolled2013

    A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01744236 Phase 4Completed70 enrolled2013

    SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

    Amsterdam UMC, location VUmc

    Type 2 Diabetes

  • NCT01843127 Phase 1Completed24 enrolled2013

    A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

    Gilead Sciences

    Type 2 Diabetes Mellitus

  • NCT01791465 Phase 4Terminated6 enrolled2013

    Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

    Vanderbilt University

    Human Immunodeficiency Virus Infection · Diabetes Mellitus

  • NCT01818648 Phase 4Withdrawn2013

    Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

    Mayo Clinic

    Short Bowel Syndrome

  • NCT01455896 Phase 3Completed4,156 enrolled2013

    A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01455857 Phase 3Completed460 enrolled2013

    A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01794429 Phase 3Completed45 enrolled2013

    Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

    Bjorn H. Ebdrup

    Obesity · Metabolic Syndrome X · Drug-induced Obesity · Schizophrenia

  • NCT02349802 Phase 1Completed3,052 enrolled2013

    Autoinjector Device Assessment Study

    AstraZeneca

    Healthy Subjects

  • NCT01652729 Phase 3Completed365 enrolled2013

    Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

    AstraZeneca

    Diabetes Type 2

  • NCT01455883 Phase 3Withdrawn2013

    A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01455922 Phase 3Withdrawn2013

    A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01455909 Phase 3Withdrawn2013

    A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03297879 Phase 4Completed230 enrolled2013

    Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

    Beijing Chao Yang Hospital

    Type2 Diabetes

  • NCT01652716 Phase 3Completed377 enrolled2013

    Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT01783717 Unknown10 enrolled2012

    Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

    Huashan Hospital

    Hypothalamic Obesity · Diabetes Mellitus

  • NCT01573806 Phase 1/2Withdrawn2012

    Pharmacology of Exenatide in Pediatric Sepsis

    Seattle Children's Hospital

    Septic Shock · Inflammation · Glucose Homeostasis · Organ Dysfunction

  • NCT01724060 Completed80 enrolled2012

    Effects of Obesity Treatments on Food Preferences and Metabolism

    Imperial College London

    Obesity · Type 2 Diabetes Mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01676116 Phase 3Completed438 enrolled2012

    The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01677104 Completed63 enrolled2012

    The Microvascular Function of GLP-1 and Its Analogues

    Katarina Kos

    Type 2 Diabetes · Obesity

  • NCT01524705 Phase 4Completed102 enrolled2012

    FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

    University of Washington

    Type 2 Diabetes

  • NCT01776788 Phase 4Completed156 enrolled2012

    Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

    The First Affiliated Hospital of Xiamen University

    Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01664624 Phase 1Completed40 enrolled2012

    Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

    AstraZeneca

    Type 2 Diabetes

  • NCT01484873 Phase 2Completed10 enrolled2012

    Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

    Vanderbilt University Medical Center

    Obesity · Overweight · Craniopharyngioma

  • NCT01590433 Phase 4Completed249 enrolled2012

    Weight Loss With Exenatide Treatment

    Jody Dushay

    Obesity

  • NCT01444898 Completed10 enrolled2012

    Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

    Children's Hospital Los Angeles

    Prader-Willi Syndrome

  • Study of laparoscopic biliopancreatic diversion modality for treatment of type 2 diabetes in patients with a BMI between 30 and 35. [Estudio y resultados de una modalidad de derivación biliopancreática laparoscópica para el tratamiento de la diabetes tipo 2 en pacientes con IMC entre 30 y 35]

    Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

    Type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01855490 Phase 1Completed17 enrolled2012

    Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

    Yale University

    Type 1 Diabetes

  • NCT01554618 Phase 3Completed84 enrolled2011

    Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

    AstraZeneca

    Children and Adolescent With Type 2 Diabetes

  • NCT01501084 Phase 1Completed34 enrolled2011

    Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

    University of California, Los Angeles

    Obesity

  • NCT01473147 Completed51 enrolled2011

    Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

    Chang Gung Memorial Hospital

    Type 2 Diabetes Mellitus

  • NCT01281228 Completed48 enrolled2011

    The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes

    Amsterdam UMC, location VUmc

    Diabetes Mellitus · Diabetes Mellitus, Type 2 · Obesity

  • NCT01373216 Phase 3Completed38 enrolled2011

    Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

    Charles University, Czech Republic

    Coronary Artery Disease · Decreased Left Ventricular Function

  • NCT01575301 Completed411 enrolled2011

    DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

    University of Dundee

    Diabetes

  • GLP Analogs for Diabetes in Wolfram Syndrome Patients

    Hadassah Medical Organization

    Diabetes Mellitus Associated With Genetic Syndrome · Wolfram Syndrome

  • NCT01342042 Phase 2Unknown36 enrolled2011

    The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

    CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01416649 Completed8 enrolled2011

    Impact of Exenatide on Sleep Duration

    University of Chicago

    Type 2 Diabetes

  • NCT01381926 Phase 4Terminated14 enrolled2011

    Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

    University of Alabama at Birmingham

    Type 2 Diabetes Mellitus · Bone Remodeling

  • NCT01297062 Phase 1Completed94 enrolled2011

    A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

    AstraZeneca

    Healthy Subjects

  • NCT02042664 Phase 3Completed44 enrolled2011

    Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

    Assistance Publique Hopitaux De Marseille

    Obesity · Diabetes

  • NCT01429506 Completed30 enrolled2011

    Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

    Post Graduate Institute of Medical Education and Research, Chandigarh

    Diabetes Mellitus · Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01269034 Phase 4Completed13 enrolled2010

    New Onset Type 1 Diabetes: Role of Exenatide

    Albert Einstein College of Medicine

    Type 1 Diabetes

  • NCT01255163 Phase 2Terminated57 enrolled2010

    A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

    National Institute on Aging (NIA)

    Alzheimer's Disease · Mild Cognitive Impairment

  • NCT01270191 Phase 4Unknown160 enrolled2010

    The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

    Taipei Veterans General Hospital, Taiwan

    Type 2 Diabetes

  • NCT01235819 Phase 4Completed20 enrolled2010

    Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

    Command Hospital, India

    Type 1 Diabetes

  • NCT01140893 Phase 2/3Unknown110 enrolled2010

    Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

    University Hospital, Caen

    Type 2 Diabetes

  • NCT01237314 Completed46 enrolled2010

    The Impact of Food on Blood Sugar in People With Type 2 Diabetes

    HealthPartners Institute

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01364584 Completed23 enrolled2010

    Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

    University of Colorado, Denver

    Type 2 Diabetes

  • NCT01237197 Phase 2Completed26 enrolled2010

    Exenatide in Extreme Pediatric Obesity

    University of Minnesota

    Obesity

  • NCT01147627 Completed416 enrolled2010

    Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

    Sun Yat-sen University

    Diabetes Mellitus, Type 2 · Newly Diagnosed

  • NCT01181986 Phase 4Completed76 enrolled2010

    The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

    Carl T. Hayden VA Medical Center

    Type 2 Diabetes Mellitus

  • NCT01156779 Phase 1Completed31 enrolled2010

    Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

    Dong-A Pharmaceutical Co., Ltd.

    Diabetes Mellitus

  • NCT01588418 Phase 4Completed15 enrolled2010

    Acute Effect of Exenatide on Brain Glucose Metabolism

    The University of Texas Health Science Center at San Antonio

    Impaired Glucose Tolerance (IGT) · Diabetes

  • NCT01174810 Phase 2Unknown40 enrolled2010

    Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

    University College, London

    Parkinson's Disease

  • NCT01144338 Phase 3Completed14,752 enrolled2010

    Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01136798 Completed18 enrolled2010

    Impact of Exenatide on Sleep in Type 2 Diabetes

    University of Chicago

    Type 2 Diabetes · Sleep Disordered Breathing

  • NCT01104701 Phase 2Completed121 enrolled2010

    A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

    AstraZeneca

    Type 2 Diabetes

  • NCT01951651 Phase 4Completed24 enrolled2010

    Effect of Exenatide on Liver and Heart Fat and Inflammation

    Baylor College of Medicine

    Type 2 Diabetes Mellitus

  • NCT01060059 Completed888 enrolled2010

    Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01089569 Completed60 enrolled2010

    Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

    HealthPartners Institute

    Type 2 Diabetes

  • NCT00747968 Phase 2/3Completed8 enrolled2010

    The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

    University of Aarhus

    Type 2 Diabetes

  • NCT01064687 Phase 3Completed978 enrolled2010

    A Study in Participants With Type 2 Diabetes Mellitus

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

  • NCT01061775 Phase 1/2Completed19 enrolled2010

    Effects of Exenatide on Hypothalamic Obesity

    Children's Hospitals and Clinics of Minnesota

    Hypothalamic Obesity

  • NCT01056549 Completed15 enrolled2010

    Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

    University Health Network, Toronto

    Hyperlipidemia

  • NCT01029886 Phase 3Completed912 enrolled2010

    Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01254123 Phase 3Unknown40 enrolled2009

    Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)

    Amsterdam UMC, location VUmc

    Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).

  • NCT01003184 Phase 3Completed222 enrolled2009

    Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01580514 Phase 4Completed127 enrolled2009

    Myocardial Protection of Exenatide in AMI

    Kyunghee University Medical Center

    Myocardial Infarction

  • NCT00960661 Phase 3Completed1,036 enrolled2009

    A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01046721 Completed8 enrolled2009

    Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

    University of Nottingham

    Type 2 Diabetes

  • NCT00964262 Phase 1Completed34 enrolled2009

    A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

    Peptron, Inc.

    Type 2 Diabetes Mellitus

  • NCT01269047 Phase 4Completed37 enrolled2009

    Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

    Albert Einstein College of Medicine

    Type 1 Diabetes

  • NCT00943917 Phase 2Completed155 enrolled2009

    Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

    Intarcia Therapeutics

    Type 2 Diabetes

  • NCT00935532 Phase 3Completed427 enrolled2009

    Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00799435 Phase 4Terminated2 enrolled2009

    Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

    Baylor College of Medicine

    Diabetes Mellitus, Type 2 · Heart Failure, Diastolic

  • NCT00917267 Phase 3Completed691 enrolled2009

    A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00950677 Phase 4Completed16 enrolled2009

    The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

    Baylor College of Medicine

    Type 2 Diabetes

  • NCT00766857 Phase 4Completed27 enrolled2009

    Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

    Amsterdam UMC, location VUmc

    Type 2 Diabetes Mellitus · Congestive Heart Failure

  • NCT00886626 Phase 2Completed12 enrolled2009

    GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

    University of Minnesota

    Obesity, Morbid

  • Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?

    Hull and East Yorkshire Hospitals NHS Trust (UK)

    Polycystic ovary syndrome, non-alcoholic steatohepatitis

  • NCT00894322 Phase 1/2Completed65 enrolled2009

    A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00856609 Phase 3Completed150 enrolled2009

    The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Weight Loss · Obesity

  • NCT00870194 Phase 4Completed255 enrolled2009

    A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00877890 Phase 3Completed254 enrolled2009

    A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00882050 Phase 1/2Completed104 enrolled2009

    Intravenous Exenatide (Byetta) During Surgery

    Thomas Jefferson University

    Euglycemia · Hypoglycemia · Hyperglycemia

  • NCT02090673 Completed1,711 enrolled2009

    Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

    AstraZeneca

    Diabetes Mellitus Type 2

  • NCT01798264 Phase 1Completed44 enrolled2009

    Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

    Intarcia Therapeutics

    Type 2 Diabetes

  • NCT00872378 Phase 2/3Unknown28 enrolled2009

    The Effects of Exenatide After Gastric Restriction

    Advanced Specialty Care

    Morbid Obesity

  • NCT00744224 Completed8 enrolled2009

    PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

    Amsterdam UMC, location VUmc

    Glucocorticoid-induced Glucometabolic Abnormalities · Glucocorticoid-induced Beta-cell Dysfunction

  • NCT01107717 Phase 4Completed318 enrolled2009

    Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

    The University of Texas Health Science Center at San Antonio

    Diabetes

  • NCT00835848 Phase 4Completed100 enrolled2009

    Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

    Rigshospitalet, Denmark

    Myocardial Infarction

  • NCT00579150 Terminated7 enrolled2009

    Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

    AstraZeneca

    Birth Defects · Type 2 Diabetes · Preterm Birth

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT01700075 Phase 4Completed97 enrolled2009

    Physical and Chemical Study of Atherosclerosis Mechanisms

    Nazarbayev University

    Myocardial Infarction · Coronary Artery Diseases · Diabetes Mellitus, Type 2 · Atherosclerosis of Femoral Artery

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT00845507 Phase 4Completed54 enrolled2008

    Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

    University of Cincinnati

    Weight Gain

  • NCT00676338 Phase 3Completed820 enrolled2008

    Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00753896 Phase 3Completed134 enrolled2008

    Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

    AstraZeneca

    Type 2 Diabetes

  • NCT00765817 Phase 3Completed261 enrolled2008

    Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes

  • NCT00775684 Completed47 enrolled2008

    Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

    University of Pennsylvania

    Pre-diabetes · Type 2 Diabetes

  • NCT00782418 Phase 1Completed27 enrolled2008

    A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

    Merck Sharp & Dohme LLC

    The Methodology Assessment of Glucose Dependent Insulin Secretion

  • NCT00845559 Phase 4Withdrawn2008

    The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

    Yale University

    Obesity · Insulin Resistance · Impaired Glucose Tolerance · Cardiovascular Disease

  • NCT00736229 Phase 4Completed40 enrolled2008

    Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

    Saint Luke's Health System

    Hyperglycemia · Acute Coronary Syndromes · Myocardial Infarction

  • NCT00701935 Phase 2Terminated80 enrolled2008

    Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

    AstraZeneca

    Diabetes Mellitus

  • NCT00729326 Phase 4Completed83 enrolled2008

    Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00717457 Phase 3Completed1,189 enrolled2008

    A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

  • NCT00948168 Phase 4Completed34 enrolled2008

    Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    Type 2 Diabetes Mellitus

  • NCT01208649 Phase 4Completed13 enrolled2008

    Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

    Ruhr University of Bochum

    Nonalcoholic Fatty Liver Disease

  • NCT00855439 Completed46 enrolled2008

    Evaluation of Exenatide in Patients With Diabetic Neuropathy

    University of Michigan

    Type 2 Diabetes Mellitus · Diabetic Peripheral Neuropathy

  • NCT00707031 Phase 3Completed639 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00658021 Phase 3Completed122 enrolled2008

    Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes

  • NCT00641056 Phase 3Completed467 enrolled2008

    Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00672399 Phase 1Completed70 enrolled2008

    Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

    AstraZeneca

    Healthy Subjects

  • NCT01076842 Phase 4Completed75 enrolled2008

    Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

    Novo Nordisk A/S

    Diabetes Type 2

  • NCT01154933 Phase 2Completed24 enrolled2008

    Exeantide in Type 2 Diabetes on Insulin

    University at Buffalo

    Type 2 Diabetes

  • NCT01435980 Phase 4Unknown60 enrolled2008

    Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

    Wu Qinan

    Type 2 Diabetes

  • NCT01021527 Phase 1Completed12 enrolled2008

    A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

    Merck Sharp & Dohme LLC

    Healthy

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT00642538 Phase 1Completed20 enrolled2008

    A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

    Mannkind Corporation

    Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT00623545 Phase 4Completed28 enrolled2008

    Bioenergetic Alterations After Exenatide Administration

    University of Wisconsin, Madison

    Healthy

  • NCT00637273 Phase 3Completed514 enrolled2008

    A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00577824 Phase 3Completed181 enrolled2008

    Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

    AstraZeneca

    Type 2 Diabetes

  • NCT00635492 Completed2,515 enrolled2008

    CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00971659 Phase 1Completed48 enrolled2008

    Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

    Profil Institut für Stoffwechselforschung GmbH

    Type 2 Diabetes

  • NCT00603239 Phase 3Completed165 enrolled2008

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01006889 Phase 4Completed24 enrolled2008

    Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

    University of Florida

    Nonalcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus

  • NCT00937079 Completed30 enrolled2007

    Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

    University Hospital, Basel, Switzerland

    Hyperinsulinism · Hypoglycemia · Insulinoma

  • NCT02084654 Phase 1Completed66 enrolled2007

    Exenatide and Weight Loss for Diabetes Prevention

    Stanford University

    Pre Diabetes · Insulin Resistance

  • NCT00546728 Phase 4Completed50 enrolled2007

    The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

    St. Paul Heart Clinic

    Impaired Glucose Tolerance

  • NCT00529204 Phase 2Terminated1 enrolled2007

    Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

    University of California, Davis

    Diabetes Complications · Fatty Liver

  • NCT00551343 Completed20 enrolled2007

    Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

    Garvan Institute of Medical Research

    Prader-Willi Syndrome

  • NCT00679042 Phase 3Active Not Recruiting21 enrolled2007

    Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

    CellTrans Inc.

    Type 1 Diabetes Mellitus

  • NCT00612794 Phase 1Completed30 enrolled2007

    A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes

  • NCT00516074 Phase 3Completed54 enrolled2007

    A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00508287 Phase 1Completed36 enrolled2007

    Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

    Bristol-Myers Squibb

    Type 2 Diabetes

  • NCT00516048 Phase 3Completed58 enrolled2007

    An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00518882 Phase 3Completed467 enrolled2007

    Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT00845182 Phase 4Completed43 enrolled2007

    Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

    The University of Texas Health Science Center at San Antonio

    Type 2 Diabetes · Healthy · Impaired Glucose Tolerance

  • NCT01432405 Phase 4Completed24 enrolled2007

    Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

    Baylor College of Medicine

    Type 2 Diabetes Mellitus

  • NCT00500370 Phase 2Completed163 enrolled2007

    A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

    AstraZeneca

    Obesity

  • NCT00477581 Phase 4Completed102 enrolled2007

    A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00518115 Phase 2Completed361 enrolled2007

    Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

  • NCT00456885 Phase 4Completed41 enrolled2007

    The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

    Beth Israel Deaconess Medical Center

    Obesity · Impaired Glucose Tolerance

  • NCT00456300 Phase 2Completed11 enrolled2007

    Role of Exenatide in Type 1 Diabetes

    Montefiore Medical Center

    Type 1 Diabetes

  • NCT00667732 Phase 4Completed41 enrolled2007

    How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

    Oregon Health and Science University

    Type 2 Diabetes

  • NCT00434954 Phase 3Completed494 enrolled2007

    Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00375492 Phase 3Completed196 enrolled2006

    Effect on Weight Loss of Exenatide Versus Placebo

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00359762 Phase 3Completed1,029 enrolled2006

    Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00359879 Phase 3Completed377 enrolled2006

    Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes

  • NCT00382239 Phase 2Completed153 enrolled2006

    A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00381342 Phase 3Completed233 enrolled2006

    Safety and Efficacy of Exenatide as Monotherapy

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00974272 Phase 4Completed39 enrolled2006

    Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

    Carl T. Hayden VA Medical Center

    Type 2 Diabetes Mellitus · Impaired Glucose Tolerance

  • NCT00650546 Phase 2/3Completed8 enrolled2006

    Role of Exenatide in NASH-a Pilot Study

    Indiana University

    Nonalcoholic Fatty Liver Disease

  • NCT00353834 Phase 4Completed72 enrolled2006

    The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

    Joslin Diabetes Center

    Type 2 Diabetes Mellitus

  • NCT00360334 Phase 3Completed235 enrolled2006

    A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

    AstraZeneca

    Type 2 Diabetes

  • NCT00344851 Phase 2Completed60 enrolled2006

    Exenatide and Metformin Therapy in Overweight Women With PCOS

    Metabolic Center of Louisiana Research Foundation

    Polycystic Ovary Syndrome

  • NCT00308139 Phase 3Completed303 enrolled2006

    Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00313001 Phase 3Completed373 enrolled2006

    Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT00254254 Phase 2Completed13 enrolled2006

    A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00324363 Phase 3Completed466 enrolled2006

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00254800 Phase 1Completed38 enrolled2005

    The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00135330 Phase 3Completed137 enrolled2005

    An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00259896 Phase 1Completed30 enrolled2005

    In-patient Study in Patients With Type 2 Diabetes Mellitus

    GlaxoSmithKline

    Type 2 Diabetes Mellitus · Diabetes Mellitus, Type 2

  • NCT00241423 Phase 2Completed30 enrolled2005

    Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00103935 Phase 2Completed45 enrolled2005

    Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00517283 Phase 1Completed17 enrolled2005

    A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00566813 Phase 1/2Completed10 enrolled2004

    Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

    University of Illinois at Chicago

    Diabetes Mellitus, Type 1

  • NCT01077323 Completed363,766 enrolled2004

    A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

    AstraZeneca

    Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies) · Healthy Subjects (Treated With no Diabetes Therapies)

  • NCT00097500 Phase 3Completed69 enrolled2004

    Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00099619 Phase 3Completed138 enrolled2004

    Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00099320 Phase 3Completed182 enrolled2004

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00099333 Phase 2Completed49 enrolled2004

    Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT01876849 Phase 3Completed275 enrolled2003

    An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00082407 Phase 3Completed505 enrolled2003

    Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00085969 Phase 2Completed99 enrolled2003

    Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00064714 Phase 2Completed47 enrolled2003

    Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

    AstraZeneca

    Diabetes Mellitus

  • NCT00082381 Phase 3Completed551 enrolled2003

    Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00111540 Phase 3Completed456 enrolled2002

    Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT01789957 Phase 3Completed225 enrolled2002

    Extension Study for 2993-112

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00044668 Phase 3Completed155 enrolled2002

    Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00044694 Phase 2Completed156 enrolled2002

    Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

  • NCT00035984 Phase 3Completed734 enrolled2002

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

  • NCT00039013 Phase 3Completed336 enrolled2002

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT00039026 Phase 3Completed377 enrolled2002

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

  • GEN-100

    Genesis Pharma S.A.

    Acute Ischemic Stroke

  • 2024-518554-17-00 Authorised, Not Started20 enrolled

    A GLP-1 receptor PET imaging add-on study within the VERA-T1D trial investigating the effects on beta cell mass (Image-VER-A-T1D)

    Radboud universitair medisch centrum Stichting

    type 1 diabetes mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Exenatide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.